India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein
18/09/2026 09:33
BUZZ-India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein ** Zydus Lifesciences ZYDU.NS to benefit from Novartis NOVN.S discontinuing its drug for neurodegenerative disorder ALS for failing to meet goals in mid-stage study, according to Bernstein analysts
** ZYDU's candidate Usnoflast's demonstration of clinically meaningful slowing of disease progression in ongoing Phase II clinical trial to be key - Bernstein rated 5 out of 5 stars overall, per LSEG
** Brokerage rates ZYDU "outperform", PT at street-high 1,457.48 rupees, per LSEG-compiled data
** 15 of 29 analysts rate ZYDU "buy" or higher, median PT 1,205 rupees - LSEG-compiled data
** ZYDU up 1.73% at 1,154.7 rupees; YTD, shares up about 26%
(Reporting by Saikeerthi in Bengaluru)
((Saikeerthi@thomsonreuters.com; (+91) 8296756080))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant